PDS Biotechnology (NASDAQ:PDSB) Earns Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of PDS Biotechnology (NASDAQ:PDSB) in a report issued on Thursday,Benzinga reports. The firm currently has a $21.00 price target on the stock.

Separately, B. Riley dropped their price target on shares of PDS Biotechnology from $9.00 to $7.00 and set a “buy” rating on the stock in a research note on Monday, November 25th. One research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $11.67.

PDS Biotechnology Stock Performance

Shares of PDSB stock opened at $1.23 on Thursday. The stock has a market capitalization of $46.98 million, a P/E ratio of -1.06 and a beta of 1.68. The company has a current ratio of 2.84, a quick ratio of 2.84 and a debt-to-equity ratio of 0.55. The firm’s 50 day moving average is $1.44 and its 200 day moving average is $2.27. PDS Biotechnology has a 12 month low of $1.13 and a 12 month high of $5.00.

Institutional Trading of PDS Biotechnology

Several institutional investors and hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC lifted its stake in PDS Biotechnology by 9.8% in the 3rd quarter. Geode Capital Management LLC now owns 415,113 shares of the company’s stock worth $1,586,000 after purchasing an additional 37,142 shares in the last quarter. Blair William & Co. IL lifted its stake in PDS Biotechnology by 29.4% in the 4th quarter. Blair William & Co. IL now owns 157,500 shares of the company’s stock worth $257,000 after purchasing an additional 35,757 shares in the last quarter. Renaissance Technologies LLC lifted its stake in PDS Biotechnology by 331.0% in the 4th quarter. Renaissance Technologies LLC now owns 100,000 shares of the company’s stock worth $163,000 after purchasing an additional 76,800 shares in the last quarter. XTX Topco Ltd lifted its stake in PDS Biotechnology by 241.8% in the 3rd quarter. XTX Topco Ltd now owns 67,182 shares of the company’s stock worth $257,000 after purchasing an additional 47,528 shares in the last quarter. Finally, Two Sigma Investments LP lifted its stake in PDS Biotechnology by 273.5% in the 4th quarter. Two Sigma Investments LP now owns 65,732 shares of the company’s stock worth $107,000 after purchasing an additional 48,132 shares in the last quarter. 26.84% of the stock is currently owned by hedge funds and other institutional investors.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.